event-driven endpoint Obstructive Sleep Apnea Status: Phase 3 Planned Focus: OSA severity reduction (apnea-hypopnea index) with CagriSema-induced weight loss Population: Adults with moderate-severe OSA and obesity Timeline: Expected enrollment 2024-2025 NASH/MAFLD Status: Phase 2 Ongoing Focus: Hepatic steatosis, inflammation, and fibrosis improvement Population: Adults with biopsy-confirmed NASH/MAFLD Timeline: Results expected 2025 Heart Failure with Preserved EF Status: Preclinical Planning Focus: HFpEF outcomes in obese patients following substantial weight loss Rationale: Obesity-HFpEF phenotype may benefit from profound weight reduction Timeline: Early development phase Pediatric Obesity Status: Phase 2 Planning Focus: Safety, tolerability, and efficacy in adolescents (12-18 years) Population: Adolescents with obesity (BMI 95th percentile) Timeline: Expected initiation 2025 Oral Formulation Development Status: Preclinical Focus: Oral bioavailability enhancement for cagrilintide using absorption enhancers Rationale: Oral delivery could improve accessibility and adherence Timeline: Research phase
"Environmental risk asse Page 460 and 461: Stumpf M, Ternes TA, Haberer K, and Page 462 and 463: Summerton L, Clark J, Greenwood R, Page 464 and 465: Stterlin H, Trittler R, Bojanowsk Page 466 and 467: urinary and synthetic ovulation-inh Page 468 and 469: Chloramphenicol in Sewage Sludge an Page 470 and 471: Chemistry 2002, 21(4):729-736
The signs of skin cancer can be subtle, but its most often identified by a funky-looking mole that changes over time
Glucagon-like peptide-1, or GLP-1, is a natural incretin hormone that is produced by the gut and helps the body to perform metabolism (breakdown and synthesis of chemical substances)
